New supplement aims to slow Parkinson's by boosting brain antioxidant levels
NCT ID NCT07064005
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether a supplement called gamma-glutamylcysteine (GGC) can increase levels of the brain's master antioxidant, glutathione, in people with early Parkinson's disease. Researchers will measure changes in brain chemistry, motor skills, thinking abilities, and gut health over the course of supplementation. The trial enrolls 12 adults aged 50–80 with confirmed Parkinson's and no dementia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSONS DISEASE (PD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UPMC Presbyterian Hospital
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Magnetic pulses to the brain may calm anxiety in Parkinson's — a trial puts it to the test
- Precision brain stimulation: which target best stops Parkinson's tremor?
- Scientists hunt for fingerprints of a genetic form of Parkinson's
- Could this pill delay Parkinson's progression? new trial begins
- New 'Phygital' therapy aims to sharpen hand skills in Parkinson's
- Ear stimulation may sharpen thinking in Parkinson's and healthy adults